Cargando…
Anticoagulation in hospitalized patients with COVID-19
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit o...
Autores principales: | Baumann Kreuziger, Lisa, Sholzberg, Michelle, Cushman, Mary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361053/ https://www.ncbi.nlm.nih.gov/pubmed/35653590 http://dx.doi.org/10.1182/blood.2021014527 |
Ejemplares similares
-
How should we use convalescent plasma therapies for the management of COVID-19?
por: Wood, Erica M., et al.
Publicado: (2021) -
Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders
por: Thompson, Philip A., et al.
Publicado: (2023) -
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022) -
Minimal information for reporting a genomics experiment
por: Dreval, Kostiantyn, et al.
Publicado: (2022) -
Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics
por: Vallelian, Florence, et al.
Publicado: (2022)